Elicio Therapeutics, Inc. 8-K Filing

Ticker: ELTX · Form: 8-K · Filed: Jun 27, 2024 · CIK: 1601485

Elicio Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyElicio Therapeutics, Inc. (ELTX)
Form Type8-K
Filed DateJun 27, 2024
Pages3
Reading Time3 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Elicio Therapeutics, Inc. (ticker: ELTX) to the SEC on Jun 27, 2024.

What are the key financial figures in this filing?

Key dollar amounts include: $0.01 (nge on which registered Common Stock, $0.01 par value per share ELTX The Nasdaq).

How long is this filing?

Elicio Therapeutics, Inc.'s 8-K filing is 3 pages with approximately 824 words. Estimated reading time is 3 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 824 words · 3 min read · ~3 pages · Grade level 10.6 · Accepted 2024-06-27 16:09:40

Key Financial Figures

  • $0.01 — nge on which registered Common Stock, $0.01 par value per share ELTX The Nasdaq

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On June 27, 2024, Elicio Therapeutics, Inc. (the "Company") issued a press release announcing preliminary disease-free survival analysis from its ongoing AMPLIFY-7P Phase 1a study of its investigational therapeutic cancer vaccine candidate, ELI-002 7P, in patients with mutated Kirsten rat sarcoma viral oncogene homolog ("mKRAS")-driven solid tumors. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. A copy of an updated version of the Company's corporate presentation, which was uploaded to the Company's website on June 27, 2024, is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein. The exhibits furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act, regardless of any general incorporation language in such filing.

01. Other Events

Item 8.01. Other Events. On June 27, 2024, the Company announced preliminary disease-free survival analysis from its ongoing AMPLIFY-7P Phase 1a study of ELI-002 7P. The Company's AMPLIFY-7P Phase 1/2 trial is assessing the safety and efficacy of the 7-peptide version of ELI-002 as adjuvant monotherapy treatment in patients with solid tumors carrying mKRAS. In April 2023, the Company initiated dosing of the Phase 1a portion of the trial enrolling 14 patients through October 2023, who are continuing to be evaluated for safety and efficacy of two ELI-002 AMP-peptide total dose levels (1.4 mg and 4.9 mg) in combination with the 10.0 mg Phase 2 dose of Amph-CpG-7909. The June 2024 preliminary data, which were based upon a May 24, 2024 data cutoff date (14 patients), showed patients receiving ELI-002 7P at the Phase 2 dose of 4.9 mg AMP-peptide (n=8) were yet to reach the median disease-free survival ("DFS") endpoint. The median follow-up for the DFS endpoint was 29.1 weeks. Further, median DFS has not been reached in patients receiving the 4.9 mg AMP-peptide dose (n=8) in comparison to 12.6 weeks for patients receiving the 1.4 mg AMP-peptide dose (n=6). Patients achieving a reduction in their tumor biomarker levels had no progression events while a median DFS of 11.0 weeks was seen for patients whose tumor biomarker did not respond to ELI-002 7P. Patients with an above median T cell response to ELI-002 7P have had no progression events as of the data cutoff date.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits . The following exhibits are being furnished herewith: Exhibit Number Exhibit Title or Description 99.1 Press Release, dated June 27, 2024 99.2 Corporate presentation dated June 27, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elicio Therapeutics, Inc. Date: June 27, 2024 By: /s/ Robert Connelly Name: Robert Connelly Title: President and Chief Executive Officer (Principal Executive Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.